Skip to content

US · OKUR · BIOTECHNOLOGY

OnKure Therapeutics, Inc. (OKUR) intrinsic value and stock valuation

$2.70as of 2026-11-21 · Mkt cap 56.61M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

OnKure Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values OKUR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from OKUR’s statements →

OnKure Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boulder, CO 80301 onkuretherapeutics.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-59.52M
20202025
Free cash flow
-$-51.87M
20202025
Total equity
$56.2M
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-62.95M-$-54.39M-$-36.93M-$-29.77M-$-39.82M
Net income-$-59.52M-$-52.67M-$-35.31M-$-29.51M-$-39.77M
EPSd-$-4.4M-$-3.95M-$-2.65M-$-2.21M-$-21.97M
Operating cash flow-$-51.83M-$-51.12M-$-34.55M-$-26.95M-$-37.98M
Capital expenditure-$-50K-$-50K-$-250K-$-1.13M-$-200K
Free cash flow-$-51.87M-$-51.17M-$-34.79M-$-28.09M-$-38.18M
Total assets$62.1M$114.9M$35.7M$16M$154M
Total debt$550K$1.08M$670K$640K$0.00
Net debt-$-58.5M-$-109.68M-$-29.2M-$-10.91M-$-124.66M
Total equity$56.2M$103.8M-$-101.84M-$-54.42M$147.2M
Cash and short-term investments$59.1M$110.8M$29.9M$11.5M$147.7M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$830K$0.00$0.00$0.00$50K
Gross profit-$-830K$0.00$0.00$0.00-$-50K
Research and development expenses$48.3M$43.8M$32.1M$25.9M$28.1M
Selling, general and administrative expenses$14.7M$10.6M$4.82M$3.9M$11.7M
Other expenses-$-830K$0.00$0.00$0.00$0.00
Operating expenses$62.1M$54.4M$36.9M$29.8M$39.8M
Cost and expenses$63M$54.4M$36.9M$29.8M$39.8M
Interest income$3.44M$2.01M$1.62M$250K$0.00
Interest expense$0.00$300K$0.00$0.00$0.00
Depreciation and amortization$830K$660K$560K$390K$50K
Ebitda-$-58.69M-$-51.71M-$-34.75M-$-29.12M-$-39.72M
Operating income-$-62.95M-$-54.39M-$-36.93M-$-29.77M-$-39.82M
Total other income/expenses, net$3.43M$1.71M$1.62M$250K$50K
Income before tax-$-59.52M-$-52.67M-$-35.31M-$-29.51M-$-39.77M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-59.52M-$-52.67M-$-35.31M-$-29.51M-$-39.77M
Weighted average shares outstanding$13.5M$13.3M$13.3M$13.3M$1.81M
Weighted average diluted shares outstanding$13.5M$13.3M$13.3M$13.3M$1.81M
Balance sheet
20252024202320222021
Cash and short-term investments$59.1M$110.8M$29.9M$11.5M$147.7M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$60.8M$113M$33.8M$13.6M$153.7M
Property, plant and equipment, net$1M$1.79M$1.91M$2.05M$210K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.28M$1.9M$1.97M$2.38M$290K
Total assets$62.1M$114.9M$35.7M$16M$154M
Accounts payable$1.43M$2.97M$3.42M$2.52M$0.00
Short-term debt$550K$540K$210K$150K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$5.92M$10.5M$7.29M$5.54M$6.2M
Long-term debt$0.00$550K$470K$490K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$170K
Total non-current liabilities$10K$550K$130.3M$64.9M$610K
Capital lease obligations$550K$1.08M$670K$640K$0.00
Total liabilities$5.93M$11.1M$137.6M$70.4M$6.81M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-214.24M-$-154.72M-$-102.05M-$-57.07M-$-84.73M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$30K
Total equity$56.2M$103.8M-$-101.84M-$-54.42M$147.2M
Total investments$0.00$0.00$0.00$0.00$23M
Total debt$550K$1.08M$670K$640K$0.00
Net debt-$-58.5M-$-109.68M-$-29.2M-$-10.91M-$-124.66M
Cash flow statement
20252024202320222021
Net income-$-59.52M-$-52.67M-$-35.31M-$-29.51M-$-39.77M
Depreciation and amortization$830K$660K$560K$390K$50K
Stock-based compensation$11.6M$4.53M$200K$50K$0.00
Change in working capital-$-4.78M-$-3.95M$10K$2.12M-$-2.8M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-4.54M-$-5.93M$1.71M$0.00$0.00
Net cash provided by operating activities-$-51.83M-$-51.12M-$-34.55M-$-26.95M-$-37.98M
Investments in property, plant and equipment-$-50K-$-50K-$-250K-$-1.13M-$-200K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-50K$15.9M-$-250K-$-1.13M-$-23.38M
Common stock issued$200K$58.9M$70K$340K$132.4M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$160K$116.1M$53.1M$26.5M$132.4M
Net change in cash-$-51.71M$80.9M$18.3M-$-1.62M$71.1M
Cash at end of period$59.1M$110.8M$29.9M$11.5M$124.7M
Operating cash flow-$-51.83M-$-51.12M-$-34.55M-$-26.95M-$-37.98M
Capital expenditure-$-50K-$-50K-$-250K-$-1.13M-$-200K
Free cash flow-$-51.87M-$-51.17M-$-34.79M-$-28.09M-$-38.18M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About OnKure Therapeutics, Inc.

        OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.

        CEO
        Nicholas A. Saccomano
        Employees
        45
        Beta
        0.30

        Explore

        Frequently asked questions

        What is the intrinsic value of OnKure Therapeutics, Inc. (OKUR)?

        InvestorsCraft does not currently publish an intrinsic value for OKUR. How the IC value is calculated.

        Is OKUR undervalued?

        InvestorsCraft does not publish an undervaluation signal for OKUR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.